Asthma remains one of the most prevalent and burdensome chronic respiratory diseases worldwide, affecting an estimated 339 million people across all age groups, geographies, and socioeconomic strata. Despite significant advances in our understanding of its mechanisms and remarkable improvements in therapeutic options, asthma continues to exact a heavy toll on patients, families, healthcare systems, and economies globally.
This reference book, Asthma: A Comprehensive Clinical Reference — From Pathophysiology to Precision Medicine, was conceived in response to the rapidly evolving landscape of asthma science and clinical practice. The emergence of precision medicine, the identification of distinct endotypes and phenotypes, the development of targeted biologic therapies, and the growing recognition of environmental and climate-related determinants have fundamentally transformed how we diagnose, classify, and manage asthma in the twenty-first century.
The text is structured to serve as both a foundational reference for students and trainees entering the field and a current, evidence-based resource for practicing clinicians, researchers, and public health professionals. Each chapter integrates the latest guidelines from the Global Initiative for Asthma (GINA 2024), landmark clinical trials, and emerging evidence from translational science.
It is the author's sincere hope that this work contributes meaningfully to the clinical armamentarium of those who dedicate their efforts to improving the lives of individuals living with asthma.
Table of Contents
Chapter 1: The Global Burden of Asthma — Epidemiology and Public Health Implications
Chapter 2: Pathophysiology — Immunology, Airway Inflammation, and Remodeling
Chapter 3: Phenotypes and Endotypes — The Era of Precision Medicine
Chapter 4: Diagnosis and Monitoring — From Spirometry to Biomarkers
Chapter 5: Classification and Severity Assessment
Chapter 6: Pharmacological Management — Step-Up Therapy and GINA 2024 Guidelines
Chapter 7: Biologic Therapies — Targeting Specific Pathways
Chapter 8: Non-Pharmacological Interventions and Pulmonary Rehabilitation
Chapter 9: Asthma in Special Populations
Chapter 10: Environmental Determinants and Climate Change
Chapter 11: Acute Severe Asthma and Status Asthmaticus
Chapter 12: Difficult-to-Treat and Severe Asthma
Chapter 13: Digital Health, Telemedicine, and Artificial Intelligence in Asthma
Chapter 14: Patient Education, Self-Management, and Action Plans
References and Further Reading
Preface
Asthma remains one of the most prevalent and burdensome chronic respiratory diseases worldwide, affecting an estimated 339 million people across all age groups, geographies, and socioeconomic strata. Despite significant advances in our understanding of its mechanisms and remarkable improvements in therapeutic options, asthma continues to exact a heavy toll on patients, families, healthcare systems, and economies globally.
This reference book, Asthma: A Comprehensive Clinical Reference — From Pathophysiology to Precision Medicine, was conceived in response to the rapidly evolving landscape of asthma science and clinical practice. The emergence of precision medicine, the identification of distinct endotypes and phenotypes, the development of targeted biologic therapies, and the growing recognition of environmental and climate-related determinants have fundamentally transformed how we diagnose, classify, and manage asthma in the twenty-first century.
The text is structured to serve as both a foundational reference for students and trainees entering the field and a current, evidence-based resource for practicing clinicians, researchers, and public health professionals. Each chapter integrates the latest guidelines from the Global Initiative for Asthma (GINA 2024), landmark clinical trials, and emerging evidence from translational science.
It is the author's sincere hope that this work contributes meaningfully to the clinical armamentarium of those who dedicate their efforts to improving the lives of individuals living with asthma.
Wachyudi Muchsin
Jakarta, 2026
Chapter 1: The Global Burden of Asthma
Epidemiology and Public Health Implications
Asthma is one of the most common non-communicable diseases (NCDs) globally, constituting a major public health challenge of the twenty-first century. The World Health Organization (WHO) estimates that approximately 339 million individuals worldwide are currently living with asthma, with projections suggesting this figure could rise to over 400 million by 2025 if current trends persist. The disease accounts for approximately 1,000 deaths per day, the vast majority of which are considered preventable with appropriate diagnosis and treatment.
1.1 Prevalence and Incidence
Asthma prevalence varies substantially across geographic regions, countries, and demographic groups. High-income countries, particularly in Australasia, North America, and Western Europe, report the highest prevalence rates, with some nations recording lifetime prevalence exceeding 20% in adult populations. Conversely, low- and middle-income countries (LMICs) carry a disproportionate share of asthma mortality, partly due to limited access to essential medications including inhaled corticosteroids (ICS).
In Southeast Asia, including Indonesia, asthma affects approximately 4–7% of the general population. National surveys in Indonesia conducted between 2018 and 2022 identified asthma as one of the top ten causes of outpatient visits to primary health centers (Puskesmas), with urban areas showing higher rates than rural counterparts, likely reflecting greater exposure to air pollution, indoor allergens, and occupational hazards.
1.2 Economic and Social Burden
The economic impact of asthma is substantial and multidimensional. Direct costs include expenditure on medications, emergency department visits, hospitalizations, and primary care consultations. Indirect costs — encompassing productivity loss, absenteeism from school and work, and caregiver burden — frequently exceed direct costs in population-level analyses.
A 2022 systematic review published in The Lancet Respiratory Medicine estimated the total economic burden of asthma across 31 European countries at approximately EUR 94 billion annually, with productivity losses accounting for over 60% of this total. In the United States, the Centers for Disease Control and Prevention (CDC) estimated annual asthma-related costs at USD 81.9 billion, inclusive of medical expenses and missed school and work days.
1.3 Disparities in Asthma Outcomes
Significant inequities exist in asthma prevalence, morbidity, and mortality. Racial and ethnic minorities, individuals of lower socioeconomic status, and those residing in high-pollution urban environments consistently demonstrate worse asthma outcomes. In the United States, Black and Puerto Rican children bear a disproportionately high burden of asthma-related emergency visits and deaths. Similar disparities have been documented in the United Kingdom and across Southeast Asia.
Social determinants of health — including housing quality, access to green spaces, occupational exposures, food security, and healthcare access — play a critical role in shaping these inequities and must be addressed through integrated health systems approaches.
Chapter 2: Pathophysiology
Immunology, Airway Inflammation, and Remodeling
Asthma is a heterogeneous disease characterized by chronic airway inflammation, variable airflow limitation, airway hyperresponsiveness (AHR), and, in a subset of patients, progressive structural airway remodeling. Understanding these interconnected pathophysiological processes is essential for the rational design of diagnostic approaches and therapeutic interventions.
2.1 The Immunological Framework
The classical immunological model of asthma involves activation of the adaptive immune system, particularly CD4+ T helper 2 (Th2) lymphocytes. Upon exposure to inhaled allergens or sensitizers, antigen-presenting cells (APCs) — primarily dendritic cells in the airway mucosa — process and present antigenic peptides to naive T cells in regional lymph nodes, promoting their differentiation into the Th2 phenotype.
Th2 cells secrete a characteristic cytokine profile dominated by interleukin-4 (IL-4), IL-5, IL-9, and IL-13. These cytokines orchestrate several key pathophysiological processes: IL-4 and IL-13 promote B-cell class switching to immunoglobulin E (IgE) production; IL-5 drives eosinophil production, maturation, and survival; IL-13 directly stimulates goblet cell hyperplasia and mucus hypersecretion; and IL-9 facilitates mast cell differentiation and survival.
Abb. in Leseprobe nicht enthalten
2.2 Innate Immune Mechanisms and Alarmins
Growing recognition of the importance of innate immunity has refined our understanding of asthma pathophysiology. The airway epithelium serves not merely as a passive physical barrier but as an active immunological sensor. In response to environmental insults — including allergens, respiratory viruses, pollutants, and proteases — epithelial cells release a set of innate cytokines collectively termed 'alarmins': thymic stromal lymphopoietin (TSLP), IL-25 (IL-17E), and IL-33.
These alarmins activate innate lymphoid cells type 2 (ILC2s), a population of lineage-negative lymphocytes that do not require prior antigen sensitization. ILC2s rapidly produce large quantities of IL-5 and IL-13, initiating and amplifying type 2 airway inflammation independently of adaptive immunity. This pathway explains, in part, the development of non-allergic asthma and virus-induced exacerbations in individuals without conventional IgE-mediated sensitization.
2.3 Airway Hyperresponsiveness
Airway hyperresponsiveness (AHR) — defined as an exaggerated bronchoconstrictor response to a wide variety of specific and non-specific stimuli — is a hallmark of asthma and a key contributor to the variable airflow limitation characteristic of the disease. AHR is quantified using bronchial provocation tests employing methacholine, histamine, mannitol, or exercise challenge.
2.4 Airway Remodeling
Chronic persistent asthma is associated with structural changes in the airway wall collectively termed 'airway remodeling.' These include: subepithelial fibrosis with thickening of the reticular basement membrane; smooth muscle hypertrophy and hyperplasia; mucous gland hyperplasia and goblet cell metaplasia; increased vascularity (angiogenesis); and deposition of extracellular matrix proteins including fibronectin, collagen, and tenascin.
Airway remodeling contributes to irreversible (or partially reversible) airflow obstruction and is associated with more severe and difficult-to-treat asthma. Current biologics targeting IL-13, IL-5, and IgE have demonstrated the capacity to attenuate some remodeling indices, though complete reversal remains elusive.
Chapter 3: Phenotypes and Endotypes
The Era of Precision Medicine
The traditional conceptualization of asthma as a single disease entity has been superseded by recognition of its profound clinical, inflammatory, and molecular heterogeneity. The field has moved toward a framework of phenotypes — observable clinical characteristics — and endotypes — distinct pathobiological mechanisms — to guide individualized treatment selection in the era of precision medicine.
3.1 Clinical Phenotypes
Clinical phenotyping relies on observable characteristics including age of onset, atopic status, trigger patterns, response to treatment, and degree of airflow obstruction. Major recognized clinical phenotypes include:
• Early-onset allergic asthma: The most prevalent phenotype, typically beginning in childhood, associated with sensitization to common aeroallergens (house dust mite, pet dander, pollen), elevated total and specific IgE, peripheral and airway eosinophilia, and generally favorable response to ICS.
• Late-onset eosinophilic asthma: Develops in adulthood (often after age 40), frequently severe, associated with nasal polyposis and non-steroidal anti-inflammatory drug (NSAID) sensitivity (Samter's triad), elevated blood and sputum eosinophils, and often corticosteroid-dependent.
• Obesity-related asthma: Characterized by non-eosinophilic inflammation, reduced lung volumes due to mechanical effects of obesity, frequent exacerbations, and attenuated response to standard ICS therapy.
• Occupational asthma: Triggered by specific workplace sensitizers or irritants; early identification and removal from exposure is critical for disease resolution.
• Exercise-induced bronchoconstriction: Transient airflow obstruction during or following exercise, present in up to 90% of asthmatic patients and also occurring in 10% of the general population.
3.2 Molecular Endotypes and Treatable Traits
The concept of 'treatable traits' — a precision medicine approach to asthma management — shifts focus from syndrome-based diagnosis toward identification of specific pathological traits amenable to targeted intervention. Two overarching inflammatory endotypes are recognized:
Abb. in Leseprobe nicht enthalten
Chapter 4: Diagnosis and Monitoring
From Spirometry to Biomarkers
Accurate and timely diagnosis of asthma is foundational to effective management and remains a clinical challenge due to the heterogeneity of presentations, symptom overlap with other respiratory conditions, and variability of airflow obstruction over time. A structured diagnostic approach integrating clinical history, objective lung function testing, and biomarker assessment is recommended by current international guidelines.
4.1 Clinical History and Symptoms
The clinical diagnosis of asthma is suggested by the presence of characteristic symptoms — wheeze, shortness of breath, chest tightness, and cough — that are variable, episodic, and typically worse at night or in the early morning. Key clinical features supporting an asthma diagnosis include:
• More than one symptom (especially in adults)
• Symptoms provoked by exercise, allergen exposure, cold air, or viral infections
• Symptoms that vary over time and in intensity
• Symptoms that worsen at night or on waking
• History of atopy (eczema, allergic rhinitis) or family history of asthma
4.2 Lung Function Testing
Spirometry remains the cornerstone of asthma diagnosis. Demonstration of variable expiratory airflow limitation is required for a definitive diagnosis. Key spirometric findings include a post-bronchodilator increase in FEV₁ of ≥12% and ≥200 mL from baseline, or an FEV₁/FVC ratio below 0.70. Excessive day-to-day variability in peak expiratory flow (PEF) >10% on twice-daily measurements over two weeks is also diagnostic.
4.3 Biomarkers in Asthma
The emergence of biomarkers has transformed asthma diagnostic precision and therapeutic decision-making. Key biomarkers currently in clinical use include:
Abb. in Leseprobe nicht enthalten
4.4 Monitoring Disease Control and Lung Function Decline
Ongoing monitoring of asthma control is essential and should encompass symptom control assessment (using validated tools such as the Asthma Control Test, ACT, or Asthma Control Questionnaire, ACQ), exacerbation frequency, medication side effects, lung function, and patient satisfaction and adherence. Lung function decline — even in well-controlled patients — should prompt escalation of monitoring and therapy.
Chapter 5: Classification and Severity Assessment
Asthma severity is classified according to the level of treatment required to achieve and maintain good symptom control, rather than symptom burden alone. The GINA 2024 guidelines categorize asthma severity as mild (controlled on GINA Steps 1–2), moderate (Steps 3–4), and severe (Step 5 or higher).
5.1 GINA Severity Classification
Abb. in Leseprobe nicht enthalten
5.2 Tools for Control Assessment
The Asthma Control Test (ACT) is a validated five-item self-administered questionnaire scoring from 5 to 25; scores ≤19 indicate uncontrolled asthma. The Asthma Control Questionnaire (ACQ) uses a seven-item format with a threshold score of 1.5 for identifying inadequate control. Both instruments demonstrate good agreement with physician-assessed control and are recommended for routine monitoring.
Chapter 6: Pharmacological Management
Step-Up Therapy and GINA 2024 Guidelines
The cornerstone of asthma pharmacotherapy is inhaled corticosteroids (ICS), which address the fundamental pathological process of airway inflammation. GINA 2024 guidelines have introduced important revisions to the treatment algorithm, most notably the abandonment of SABA (short-acting beta-2 agonist) monotherapy as reliever therapy in favor of ICS-containing regimens at all treatment steps.
6.1 Controller vs. Reliever Therapy
Controller medications are taken regularly to maintain clinical control of asthma through their anti-inflammatory effects. Reliever (rescue) medications provide rapid symptomatic relief of acute bronchoconstriction. The GINA 2024 landmark shift recommends that all patients with asthma receive ICS-containing therapy, either as maintenance or as combination maintenance and reliever therapy (MART), to reduce the risk of life-threatening exacerbations.
6.2 Inhaled Corticosteroids — Pharmacology and Clinical Considerations
Inhaled corticosteroids act via glucocorticoid receptor-mediated suppression of pro-inflammatory gene transcription, reducing eosinophilic airway inflammation, goblet cell hyperplasia, and AHR. They represent the most effective long-term controller medication across all asthma severity levels. Commonly used ICS include beclomethasone dipropionate (BDP), budesonide, fluticasone propionate (FP), fluticasone furoate (FF), ciclesonide, and mometasone furoate.
6.3 Long-Acting Beta-2 Agonists (LABAs) and SMART/MART Strategy
LABAs — salmeterol and formoterol — are the most important add-on therapy to ICS in moderate-to-severe asthma. Formoterol's rapid onset of action (within 1–3 minutes) makes it uniquely suitable for use as both a maintenance and reliever medication in the SMART (Symbicort Maintenance And Reliever Therapy) or MART strategy. Multiple large randomized controlled trials and real-world studies have demonstrated that ICS/formoterol MART reduces severe exacerbation rates by 30–50% compared to fixed-dose ICS/LABA regimens with separate SABA reliever.
6.4 Long-Acting Muscarinic Antagonists (LAMAs)
Tiotropium bromide, delivered via Respimat soft-mist inhaler, is the only LAMA with regulatory approval as add-on therapy for asthma (in patients ≥6 years with a history of exacerbations). Its addition to ICS-LABA therapy at Steps 4–5 has been shown to modestly improve FEV₁, reduce exacerbations, and delay time to first severe exacerbation. Umeclidinium is under investigation as additional LAMA option in asthma.
Chapter 7: Biologic Therapies
Targeting Specific Pathways
The development and regulatory approval of monoclonal antibody-based biologic therapies represents one of the most significant advances in asthma management over the past two decades. These agents target specific molecules within the inflammatory cascade, enabling truly personalized treatment in severe asthma uncontrolled on conventional therapy.
7.1 Approved Biologic Agents
Abb. in Leseprobe nicht enthalten
7.2 Biomarker-Guided Biologic Selection
Patient selection for biologic therapy requires careful biomarker profiling. Blood eosinophil count is the most accessible T2 biomarker: counts ≥300 cells/μL favor anti-IL-5 therapy; counts ≥150 cells/μL combined with elevated FeNO (≥25 ppb) or IgE-mediated atopy favor dupilumab or omalizumab; tezepelumab demonstrates efficacy regardless of baseline eosinophil count, making it the broadest-spectrum biologic currently available.
7.3 Future Pipeline
The biologic pipeline for asthma continues to expand. Key agents in late-stage development include: anti-IL-25 (anti-IL-17E) antibodies; anti-CRTH2 agents; targeted small molecules including oral CRTH2 antagonists, JAK inhibitors (e.g., abrocitinib) being evaluated for type 2 airway disease; and inhaled biologics designed to deliver high local concentrations with minimal systemic exposure.
Chapter 8: Non-Pharmacological Interventions
and Pulmonary Rehabilitation
Pharmacological therapy, while central to asthma management, must be complemented by non-pharmacological strategies addressing trigger avoidance, lifestyle modification, comorbidity management, and rehabilitation. These approaches are integral to the holistic care of patients with asthma.
8.1 Environmental Control and Trigger Avoidance
Identification and mitigation of individual asthma triggers is foundational to reducing symptom burden and exacerbation frequency. For house dust mite (HDM)-sensitized patients, evidence-based measures include the use of allergen-impermeable mattress and pillow covers, regular high-temperature laundering of bedding, reduction of indoor humidity, and removal of carpets where feasible.
Tobacco smoke — active and passive — remains a critical modifiable risk factor for asthma. Smoking cessation interventions, including pharmacotherapy (varenicline, nicotine replacement therapy, bupropion) and behavioral support, must be actively offered at every clinical encounter. E-cigarette and vaping use, increasingly prevalent particularly among adolescents, is associated with worsening asthma outcomes and should be specifically addressed.
8.2 Allergen Immunotherapy
Subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) represent the only disease-modifying treatment available for allergic asthma, capable of inducing sustained tolerance to specific allergens. Both modalities have demonstrated efficacy in reducing asthma symptoms, bronchial AHR, and long-term medication requirements. SLIT is recommended as an add-on therapy in HDM-sensitized adults and adolescents with HDM-driven allergic rhinitis and mild-to-moderate asthma uncontrolled on ICS (GINA 2024 Step 3).
8.3 Pulmonary Rehabilitation
While pulmonary rehabilitation (PR) is most extensively studied in COPD, a growing evidence base supports its benefits in severe and difficult-to-treat asthma. Structured exercise training improves exercise capacity, reduces exacerbation frequency, attenuates exercise-induced bronchoconstriction, and enhances quality of life. Inspiratory muscle training (IMT) has shown particular promise in patients with dysfunctional breathing patterns.
8.4 Bronchial Thermoplasty
Bronchial thermoplasty (BT) is an endoscopic procedure delivering radiofrequency energy to the airway wall to reduce smooth muscle mass, thereby attenuating bronchoconstriction. Approved for adults with severe persistent asthma uncontrolled on maximized pharmacotherapy, BT reduces the frequency of severe exacerbations and emergency healthcare utilization in carefully selected patients. Patient selection, technique standardization, and long-term surveillance remain areas of ongoing investigation.
Chapter 9: Asthma in Special Populations
The management of asthma requires adaptation to the unique physiological, pharmacological, and psychosocial characteristics of specific patient populations. These include children, pregnant women, elderly individuals, athletes, and patients with significant comorbidities.
9.1 Childhood Asthma
Asthma is the most prevalent chronic disease of childhood globally. Diagnostic challenges in young children include the inability to perform reliable spirometry in children under five years of age, the high prevalence of transient viral wheeze in infancy and early childhood that does not represent classical asthma, and the difficulty of distinguishing early-onset asthma from other causes of recurrent wheeze.
The Asthma Predictive Index (API) remains a clinically useful tool for identifying preschool wheezers at elevated risk for persistent asthma by school age. In children aged 6 years and older, the diagnostic approach mirrors that of adults, with spirometry and bronchial provocation tests as cornerstones. Treatment follows the same stepwise GINA framework, though specific formulations, devices, and age-appropriate education strategies differ significantly.
9.2 Asthma in Pregnancy
Asthma affects approximately 8–13% of pregnancies and is one of the most common medical conditions complicating pregnancy. Disease control during pregnancy has critical implications for both maternal and fetal outcomes. Poorly controlled asthma is associated with preeclampsia, gestational diabetes, preterm birth, low birth weight, and increased cesarean delivery rates.
The cardinal principle of asthma management in pregnancy is that the risks of uncontrolled asthma far outweigh any theoretical risks of pharmacological treatment. ICS therapy is considered safe throughout pregnancy, as is the use of SABAs for relief and LABAs as add-on therapy. Among biologic agents, data on safety in pregnancy are limited; dupilumab and mepolizumab have been used in severe cases with apparent safety, though formal recommendation awaits larger datasets.
9.3 Asthma in the Elderly
Asthma in older adults is frequently underdiagnosed, misattributed to cardiac causes or COPD, and undertreated. Age-related changes in lung physiology — including reduced lung elastic recoil, decreased respiratory muscle strength, and blunted perception of bronchoconstriction — alter the clinical presentation. The coexistence of COPD (asthma-COPD overlap, ACO) in this population requires careful differentiation as treatment implications differ.
9.4 Occupational Asthma
Occupational asthma (OA) accounts for approximately 10–15% of adult-onset asthma in industrialized countries. Over 250 workplace agents have been identified as sensitizers or irritants capable of causing or exacerbating asthma. High-risk occupations include baking (flour dust), healthcare (latex, cleaning products), spray painting (isocyanates), woodworking, and laboratory animal work. Early identification and removal from exposure is paramount, as continued exposure leads to irreversible airway changes.
Chapter 10: Environmental Determinants and Climate Change
The intersection of asthma and environmental health represents one of the most pressing current challenges in respiratory medicine and public health. Outdoor and indoor air pollution, climate change, urbanization, biodiversity loss, and changing allergen landscapes are converging forces reshaping the epidemiology and severity of asthma globally.
10.1 Air Pollution and Asthma
Ambient air pollutants — including particulate matter (PM₂.₅ and PM₁₀), ozone (O₃), nitrogen dioxide (NO₂), and sulfur dioxide (SO₂) — are well-established triggers of asthma exacerbations and may contribute to incident asthma development. Epidemiological studies consistently demonstrate dose-dependent associations between elevated ambient PM₂.₅ concentrations and emergency department visits for asthma, hospitalizations, and mortality.
In Southeast Asia, including Indonesia, seasonal biomass burning events (peat fires, agricultural burning) cause acute spikes in regional air pollution indices, leading to demonstrable increases in asthma-related healthcare utilization. The 2015 Southeast Asian haze crisis, estimated to have caused over 100,000 premature deaths across the region, remains a stark illustration of this relationship.
10.2 Climate Change and Changing Allergen Landscape
Climate change exerts multiple, interacting effects on asthma through: extended and intensified pollen seasons (linked to rising temperatures and elevated atmospheric CO₂ stimulating plant growth and pollen production); increased ground-level ozone formation from photochemical reactions intensified by heat; greater frequency and severity of thunderstorm asthma events (caused by osmotic rupturing of pollen grains releasing respirable starch particles during thunderstorms); and increased wildfire frequency generating hazardous particulate matter at continental scales.
10.3 Health Equity and Environmental Justice
The burden of environmental triggers disproportionately falls on socially and economically disadvantaged communities — those living near industrial facilities, high-traffic roadways, or in poorly ventilated housing — resulting in a convergence of environmental injustice and health inequity in asthma outcomes. Addressing these disparities requires coordinated policy responses spanning urban planning, emission controls, green infrastructure investment, and equitable access to healthcare.
Chapter 11: Acute Severe Asthma and Status Asthmaticus
Acute severe asthma represents one of the most time-critical emergencies in respiratory medicine. Despite decades of awareness and improved preventive strategies, asthma exacerbations continue to cause preventable morbidity and mortality worldwide. Recognition, rapid assessment, and aggressive early management are life-saving.
11.1 Classification of Exacerbation Severity
Abb. in Leseprobe nicht enthalten
11.2 Pharmacological Management of Acute Attacks
First-line treatment for acute asthma exacerbations includes: short-acting beta-2 agonists (salbutamol/albuterol) delivered by metered-dose inhaler with spacer (equivalent to nebulization in mild-moderate attacks) or nebulizer in severe attacks; ipratropium bromide as an adjunct in moderate-to-severe exacerbations (reduces hospitalization); systemic corticosteroids (oral prednisolone 40–50 mg/day or IV hydrocortisone) initiated early; and controlled supplemental oxygen to maintain SaO₂ 93–95%.
Intravenous magnesium sulfate (2 g over 20 minutes) is recommended for severe exacerbations not responding to initial bronchodilator therapy. Its mechanism involves inhibition of smooth muscle contraction via calcium antagonism. Multiple trials confirm modest but meaningful improvements in lung function and reductions in hospitalization rates.
Chapter 12: Difficult-to-Treat and Severe Asthma
Severe asthma — defined as asthma that remains uncontrolled despite adherence to maximized optimized therapy — affects approximately 5–10% of the asthma population yet accounts for over 50% of asthma-related healthcare costs and a disproportionate burden of morbidity and mortality. Distinguishing 'true' severe asthma from difficult-to-treat asthma (where poor control is attributable to modifiable factors) is clinically imperative.
12.1 Systematic Assessment of Difficult-to-Treat Asthma
Before escalating to biologic therapy or accepting a diagnosis of severe asthma, a structured systematic assessment is required to address the following domains:
1. Adherence assessment: Objective measurement (electronic monitoring, pharmacy refill records, plasma drug levels) routinely reveals that 50–75% of patients prescribed ICS are non-adherent, with significant consequences for disease control.
2. Inhaler technique assessment: Suboptimal technique is observed in >50% of patients in clinical practice; incorrect technique renders even optimal ICS-LABA therapy ineffective.
3. Comorbidity evaluation: Conditions including allergic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP), gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), obesity, vocal cord dysfunction (VCD/PVFM), dysfunctional breathing, and anxiety/depression commonly masquerade as or amplify asthma.
4. Trigger exposure assessment: Ongoing occupational, allergen, or NSAID exposure; tobacco use or vaping; household dampness and mold.
5. Diagnostic confirmation: Approximately 25–30% of patients labeled as having severe asthma on clinical grounds have alternative or additional diagnoses when objectively assessed.
Chapter 13: Digital Health, Telemedicine, and Artificial Intelligence in Asthma
The digital health revolution is transforming asthma monitoring, management, and research. Smartphones, connected inhalers, wearable sensors, mobile health applications, electronic patient-reported outcomes, and artificial intelligence-driven analytical platforms are collectively reshaping the asthma care paradigm toward continuous, personalized, and proactive management.
13.1 Connected Inhalers and Electronic Monitoring
Electronic inhaler monitors — including sensor attachments (Adherium Smartinhaler, Propeller Health) and built-in sensors in smart inhalers — record the date, time, and location of each actuation, enabling unprecedented insight into real-world inhaler use patterns, adherence, and technique. Studies demonstrate that electronic monitoring-based feedback interventions improve ICS adherence by 20–40% and reduce exacerbation frequency.
13.2 Artificial Intelligence in Asthma
Machine learning and deep learning algorithms are being applied across multiple dimensions of asthma care:
• Phenotype and endotype classification: Unsupervised clustering algorithms applied to large clinical datasets (U-BIOPRED, ADEPT, SARP) have identified previously unrecognized asthma phenotypic clusters with distinct genetic, inflammatory, and clinical profiles.
• Exacerbation prediction: AI models integrating environmental monitoring data (air quality, pollen counts, humidity), electronic health records, patient-reported symptoms, and inhaler use data can predict exacerbation risk days in advance with AUC >0.80 in validation cohorts.
• Radiological analysis: Deep learning systems applied to CT and chest radiograph data demonstrate accuracy comparable to expert radiologists in identifying structural airway abnormalities, air trapping, and bronchiectasis.
• Natural language processing (NLP): Automated extraction of asthma-relevant clinical information from unstructured electronic health records enables population-level phenotyping and quality improvement initiatives.
13.3 Telemedicine in Asthma Care
The COVID-19 pandemic catalyzed rapid adoption of telemedicine in asthma care. Subsequent evidence supports the non-inferiority of virtual asthma consultations compared to in-person visits for stable patients in terms of symptom control, exacerbation rates, and patient satisfaction. Hybrid care models incorporating in-person assessment for new diagnoses, spirometry, and biologic initiation alongside virtual follow-up are emerging as the dominant paradigm in high-income settings.
Chapter 14: Patient Education, Self-Management, and Written Asthma Action Plans
Patient education and supported self-management are internationally recognized as essential components of comprehensive asthma care. Evidence consistently demonstrates that structured self-management education — particularly when combined with a written asthma action plan (WAAP) — reduces asthma-related emergency department visits by 30–40%, hospitalizations by 40%, unscheduled medical visits, and days off work or school.
14.1 Core Components of Asthma Education
• Understanding the disease: What asthma is, the difference between inflammation and bronchoconstriction, and why both must be addressed.
• Medication literacy: Differences between controller and reliever medications, correct inhaler technique (device-specific, demonstrated and returned), and the critical importance of not stopping ICS when feeling well.
• Trigger identification and avoidance: Personalized identification of the patient's specific triggers with practical mitigation strategies.
• Symptom monitoring and peak flow monitoring: Recognizing early warning signs of deteriorating control and knowing when to seek medical care.
• Written Asthma Action Plan: A personalized document describing daily therapy, how to recognize and respond to worsening asthma (green/yellow/red zones), and when to call for emergency services.
14.2 The Written Asthma Action Plan
The WAAP is the single most evidence-based tool in asthma self-management support. Effective WAAPs are individualized, use clear non-technical language, incorporate visual aids (traffic light systems), specify symptom- or PEF-based triggers for action, detail precise medication adjustments, and provide emergency contact information. Digital WAAPs accessible via smartphone applications are increasingly preferred by younger patients.
14.3 Shared Decision-Making
Modern asthma management emphasizes a partnership between the patient and healthcare team founded on shared decision-making (SDM). SDM in asthma integrates clinical evidence, patient preferences, treatment goals, and practical barriers (cost, inhaler device preference, adherence concerns, occupational constraints) into a collaborative management plan. Patients engaged through SDM demonstrate better adherence, greater treatment satisfaction, and improved clinical outcomes.
References and Further Reading
British Thoracic Society / SIGN. British Guideline on the Management of Asthma. 2023 Update.
Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022;386:157–171.
European Respiratory Society/American Thoracic Society Task Force. Definition, Evaluation and Treatment of Severe Asthma. Eur Respir J. 2014;43(2):343–373.
GALATHEA/TERRANOVA: Bleecker ER et al. Efficacy and Safety of Benralizumab for Patients with Severe Asthma Uncontrolled with High-Dosage ICS-LABA. Lancet. 2016;388(10056):2115–2127.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024. Available at: www.ginasthma.org
Holgate ST, Wenzel S, Postma DS et al. Asthma. Nat Rev Dis Primers. 2015;1:15025.
Ikrar, Taruna, Wachyudi Muchsin, and Alfi Sophian. "Maternal immunization against group B Streptococcus: Immune correlates, microbiome trade-offs, and global implementation challenges."Vaccine 77 (2026): 128381.
Ikrar, Taruna, Wachyudi Muchsin, and Alfi Sophian. "mRNA Vaccine Platforms and Lipid Nanoparticle Delivery Systems: Molecular Advances, Clinical Breakthroughs, and Regulatory Perspectives (2020–2025)." (2026).
Ikrar, Taruna, Wachyudi Muchsin, and Alfi Sophian. "Predictive Processing and Active Inference: A Comprehensive Review of Theoretical Foundations, Neural Mechanisms, and Clinical Implications in Cognitive Science."Journal of NeuroPhilosophy 5.1 (2026).
INNOVATE: Humbert M et al. Benefits of Omalizumab as Add-On Therapy in Patients with Severe Persistent Asthma. Allergy. 2005;60(3):309–316.
LIBERTY ASTHMA QUEST: Castro M et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378:2486–2496.
MENSA Trial: Ortega HG et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med. 2014;371:1198–1207.
Menzies-Gow A et al. Treatable Traits: A New Paradigm for 21st-Century Management of Chronic Airway Diseases. Eur Respir J. 2020;56(1):1–12.
National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3. NIH/NHLBI, 2022 Update.
NAVIGATOR Trial: Menzies-Gow A et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384:1800–1809.
Papi A, Brightling C, Pedersen SE, Rabe KF. Asthma. Lancet. 2018;391(10122):783–800.
Skloot GS. The Endophenotypes of Asthma. Clin Chest Med. 2019;40(1):2–11.
Sophian, Alfi, Dewi Sulanjari, and Andhika Harumanto. "Global implications of recent changes in US vaccine policy: ethical and trust challenges for immunization programs."Vaccine 77 (2026): 128393.
Sophian, Alfi, et al. "Global Vaccine Confidence at a Crossroads: Immunisation Coverage Declines, Misinformation, and the Future of Vaccine Policy."Reviews in Medical Virology 36.3 (2026): e70149.
[...]
Jetzt kaufen
- Arbeit zitieren
- Wachyudi Muchsin (Autor:in), 2026, Asthma. A Comprehensive Clinical Reference, München, GRIN Verlag, https://www.grin.com/document/1722284
